ArticleFrontiers in cellular and infection microbiology2025
Safe and efficient transportation of clinical samples for molecular detection of African swine fever virus.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) continues to devastate swine populations across the globe. The causative agent, ASF virus (ASFV), is very stable and can remain infectious over long periods of time especially in contaminated blood and tissue samples. Therefore, the transport of clinical samples from the field to diagnostic laboratories requires special precautions to reduce the risk of spreading the disease. Inactivation of ASFV in the clinical samples prior to transporting to the lab eliminates the risk and the requirement of higher biosafety facilities to perform ASF diagnostics. This study evaluated the use of a commercial molecular transport medium (MTM) to inactivate ASFV and stabilize the viral DNA in cell culture and clinical samples collected from pigs inoculated with different ASFV strains. In all the sample types tested, complete inactivation of ASFV was observed, without affecting the subsequent detection of ASFV genomic material by real time polymerase chain reaction (real time PCR). The MTM preserved the stability of ASFV genomic material eliminating the need to refrigerate clinical samples. The data shows that the MTM can be used reliably to ensure safety and stability of routine clinical samples such as whole blood, spleen swabs and alternative sample types such as oral fluid, allowing expansion and streamlining ASF molecular diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.